---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-070901"
form_type: "8-K"
ticker: "CLYM"
cik: "0001768446"
company_name: "Climb Bio, Inc."
filed_at: "2025-05-14T23:59:59+00:00"
generated_at: "2026-05-21T09:21:28.205553+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Climb Bio Q1 cash $197.8M; pipeline on track for 2025 milestones

## Summary
- Cash and marketable securities $197.8M; expected to fund operations through 2027.
- R&D expense $17.3M including $9.0M upfront to Mabworks for CLYM116 license.
- Budoprutug Phase 2 pMN FDA-cleared; ITP and SLE trials on track for H1 2025 initiation.
- CLYM116 IND/CTA submission expected H2 2025 with preclinical data in H2.
- Appointed Kim Drapkin and Bo Cumbo as independent directors; Perrin Wilson as CBO.

## SEC filing metadata
- accession: 0000950170-25-070901
- form_type: 8-K
- ticker: CLYM
- cik: 0001768446
- company_name: Climb Bio, Inc.
- filed_at: 2025-05-14T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1768446/000095017025070901/0000950170-25-070901-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1768446/000095017025070901/clym-20250514.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-070901
- JSON: https://secwatch.observer/filing/0000950170-25-070901.json
- Plain text: https://secwatch.observer/filing/0000950170-25-070901.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.